Abstract
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (r/r) large B cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is asso-ciated with poor response to treatment. We tested whether an MYC-driven polyamine signature, as a liquid biopsy, is predictive of response to anti-CD19 CAR-T therapy in patients with r/r LBCL. Elevated plasma acet-ylated polyamines were associated with non-durable response. Concordantly, increased expression of sper-midine synthase, a key enzyme that regulates levels of acetylated spermidine, was prognostic for survival in r/r LBCL. A broad metabolite screen identified additional markers that resulted in a 6-marker panel (6MetP) consisting of acetylspermidine, diacetylspermidine, and lysophospholipids, which was validated in an inde-pendent set from another institution as predictive of non-durable response to CAR-T therapy. A polyamine centric metabolomics liquid biopsy panel has predictive value for response to CAR-T therapy in r/r LBCL.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin
Chemie und Pharmazie > Department Biochemie |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
500 Naturwissenschaften und Mathematik > 540 Chemie |
ISSN: | 2666-3791 |
Sprache: | Englisch |
Dokumenten ID: | 112475 |
Datum der Veröffentlichung auf Open Access LMU: | 02. Apr. 2024, 07:36 |
Letzte Änderungen: | 02. Apr. 2024, 07:36 |